Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 71 of 1543 for:    Androgens

EXTEND Exercise Trial

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02256111
Recruitment Status : Completed
First Posted : October 3, 2014
Results First Posted : April 18, 2019
Last Update Posted : April 18, 2019
Sponsor:
Information provided by (Responsible Party):
Duke University

Brief Summary:
This study will examine the effect of supervised exercise training on cardiopulmonary function in men receiving the combination of enzalutamide (ENZ) and androgen deprivation therapy (ADT) for treatment of non-metastatic, hormone-naïve prostate cancer. No study to date has examined the efficacy, tolerability, and safety of exercise training to prevent and/or mitigate common adverse toxicities in men receiving combination androgen suppression therapy for hormone-naïve prostate cancer.

Condition or disease Intervention/treatment Phase
Non-metastatic, Hormone naïve Prostate Cancer Drug: Enzalutamide Drug: Androgen deprivation therapy Behavioral: Supervised exercise training Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 26 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: EXTEND: Safety and Efficacy of EXercise Training in Men Receiving ENzalutamide in Combination With Conventional Androgen Deprivation Therapy for Hormone Naïve Prostate Cancer
Actual Study Start Date : May 13, 2015
Actual Primary Completion Date : February 21, 2018
Actual Study Completion Date : July 17, 2018

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: ENZ+ADT+Usual care
The usual care arm will receive treatment with enzalutamide with androgen deprivation therapy, with no supervised exercise training.
Drug: Enzalutamide
Other Name: Xtandi

Drug: Androgen deprivation therapy
Experimental: ENZ+ADT+Exercise
The ENZ+ADT+Exercise arm will receive treatment with enzalutamide plus androgen deprivation therapy along with supervised exercise training.
Drug: Enzalutamide
Other Name: Xtandi

Drug: Androgen deprivation therapy
Behavioral: Supervised exercise training



Primary Outcome Measures :
  1. Change in VO2peak in Usual Care Versus Exercise Training Arms [ Time Frame: From week 1 to week 17 ]
    Mean change in peak oxygen uptake (VO2peak) from week 1 to week 17 in the usual care and exercise training groups


Secondary Outcome Measures :
  1. 17-week Change in Functional Capacity as Measured by Chair-stand Test [ Time Frame: Baseline to 17 weeks ]
    Mean change in number of seconds to perform the chair-stand test between baseline and week 17. This test measures the time taken to complete 5 repetitions of the sit-to-stand maneuver from a chair without an arm rest at 43 cm in height and 47.5 cm in depth. This test provides an indicator of functional performance of lower body strength; quicker times indicate greater strength

  2. 17-week Change in Upper and Lower Extremity Maximal Muscular Strength [ Time Frame: Baseline to 17 weeks ]
    Mean change in upper and lower extremity maximal muscular strength as measured by the voluntary one-repetition max (1-RM) and muscular endurance as measured by 70% of 1-RM between week 17 and baseline

  3. Effects on Serum Glucose [ Time Frame: Baseline to 17 weeks ]
    Mean change in fasting serum glucose between week 17 and baseline.

  4. Change in the Effect on Patient Reported Outcomes (PROs) of Interest Over Time [ Time Frame: Baseline to 17 weeks ]
    Mean change in PROs aggregate score between week 17 and baseline. PROs include the FACT-Prostate (FACT-P, range 0 to 104), FACIT-Fatigue (FACIT-F, range 0 to 52), and the Godin Leisure Questionnaire. Higher scores indicate better quality of life.

  5. Eligibility Rate [ Time Frame: 29 months from study initiation ]
    Eligibility rate is defined as the number of subjects found to be eligible divided by the number approached for the study. Note that ineligible subjects are not randomized. This is reported as a percent.

  6. Acceptance Rate [ Time Frame: 29 months from study initiation ]
    Acceptance rate is defined as the number of patients agreeing to participate divided by total number randomized. This is reported as a percent.

  7. Adherence Rate [ Time Frame: 48 days ]
    Adherence rate is defined as the percentage of days that each patient fulfilled the assigned exercise prescription of the 48 days. The median percentage is reported.

  8. Attrition Rate [ Time Frame: 16 weeks ]
    Attrition rate is defined as the percent of subjects who complete the 16 week exercise training program. This outcome applies only to the exercise arm.

  9. 17-week Change in Functional Capacity as Measured by Time Up and Go Test [ Time Frame: Baseline to 17 weeks ]
    Mean change in number of seconds to complete the timed up and go test between week 17 and baseline. This test requires patients to stand up from a chair with armrests, walk 3m, turn around, return to the chair, and sit down

  10. 17-week Change in Functional Capacity as Measured by Six Minute Walk Test [ Time Frame: Baseline to 17 weeks ]
    Mean change in distance covered during the six minute walk test between week 17 and baseline. This test requires patients to cover the longest distance possible in six minutes under the supervision of an exercise physiologist or designee.

  11. 17-week Change in Muscle Cross-sectional Area (CSA) [ Time Frame: Baseline to 17 weeks ]
    Mean change in muscle cross sectional area of the dominant quadricep, hamstring, and total mid-thigh between week 17 and baseline. Cross-sectional area was measured using magnetic resonance imaging with a 3.0T-scanner.

  12. Effects on Serum Insulin [ Time Frame: Baseline to 17 weeks ]
    Mean change in fasting serum insulin between week 17 and baseline.

  13. Effects on Blood Hemoglobin (Hgb) [ Time Frame: Baseline to 17 weeks ]
    Mean change in blood hemoglobin (Hgb) A1C between week 17 and baseline.

  14. Effects on Body Composition [ Time Frame: Baseline to 17 weeks ]
    Mean change in lean body mass and fat body mass between week 17 and baseline as measured by a DEXA Scan.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Male age ≥ 18 years.
  2. Histologically-confirmed adenocarcinoma of the prostate.
  3. Completion of appropriate prior treatment with local therapy (i.e., prostatectomy, radiation therapy or equivalent), per NCCN Guidelines.
  4. Detectable PSA, defined as PSA ≥0.01 ng/ml
  5. Appropriate for treatment with ADT in the opinion of the treating physician.
  6. Serum total testosterone ≥150 ng/dL (5.2 nmol/L).
  7. ECOG performance status of ≤ 1 (Appendix A)
  8. Planned treatment with castration therapy (GnRH agonist/antagonist) for ≥8 months.
  9. Must not have any of the following absolute contraindications to cardiopulmonary exercise testing and/or aerobic training as determined by the attending oncologist:

    Absolute Contraindications

    • Acute myocardial Infarction (within 3-5 days of any planned study procedures)
    • Unstable angina
    • Uncontrolled arrhythmia causing symptoms or hemodynamic compromise
    • Recurrent syncope
    • Active endocarditis
    • Acute myocarditis or pericarditis
    • Symptomatic severe aortic stenosis
    • Uncontrolled heart failure
    • Acute (within 3 months) pulmonary embolus or pulmonary infarction
    • Thrombosis of lower extremities
    • Suspected dissecting aneurysm
    • Uncontrolled asthma
    • Pulmonary edema
    • Room air desaturation at rest <85%
    • Respiratory failure
    • Acute non-cardiopulmonary disorders that may affect exercise performance or be aggravated by exercise (i.e. infection, renal failure, thyrotoxicosis)
    • Mental impairment leading to inability to cooperate.
  10. Able to swallow enzalutamide and comply with study requirements.
  11. Must be able to complete an acceptable cardiopulmonary exercise test (CPET) at baseline (see Section 9), defined as at least one of the following:

    • Achieving a plateau in oxygen consumption concurrent with an increase in power output;
    • Respiratory exchange ratio ≥ 1.1 (RER);
    • Volitional exhaustion with a rating of perceived exertion ≥ 17 (RPE)
  12. Must be able to complete an acceptable muscular strength test (assessed using calculated one-repetition maximum (1-RM)) at baseline (see Section 9), in the opinion of the fitness specialist, exercise physiologist, or trained designee administering the test.
  13. Life expectancy of ≥ 12 months.
  14. Must use a condom if having sex with a pregnant woman.
  15. Male subject and his female partner who is of childbearing potential must use 2 acceptable methods of birth control (one of which must include a condom as a barrier method of contraception) starting at screening and continuing throughout the study period and for 3 months after final study drug administration. Two acceptable methods of birth control thus include the following:

    • Condom (barrier method of contraception); AND

    One of the following is required:

    • Established use of oral, or injected or implanted hormonal method of contraception by the female partner;
    • Placement of an intrauterine device (IUD) or intrauterine system (IUS) by the female partner;
    • Additional barrier method: Occlusive cap (diaphragm or cervical/vault caps) with spermicidal foam/gel/film/cream/suppository by the female partner;
    • Tubal ligation in the female partner;
    • Vasectomy or other procedure resulting in infertility (e.g., bilateral orchiectomy), for more than 6 months
  16. Subjects must have normal organ and marrow function as defined below:

    • absolute neutrophil count >1,500/µL
    • platelets >100,000/µL
    • total bilirubin <2.5 X institutional upper limit of normal
    • AST(SGOT)/ALT(SGPT) <2.5 X institutional upper limit of normal
    • Creatinine ≤ 2.0 OR creatinine clearance >30 mL/min/1.73 m2 for subjects with creatinine levels above institutional normal.

Exclusion Criteria:

  1. Definite evidence of metastatic prostate cancer, in the opinion of the treating physician. Pelvic and retroperitoneal lymph nodes < 2.0 cm in short axis are allowed.
  2. Subjects who have had treatments with GnRH agonists/antagonists and/or anti-androgens within 1 year of randomization.
  3. Use of herbal products that may have hormonal anti-prostate cancer activity and/or are known to decrease PSA values (e.g., saw palmetto) or systemic corticosteroids for prostate cancer within 4 weeks of day 29 visit (start of Enzalutamide and ADT).
  4. Subjects who have had radiotherapy within 12 weeks prior to entering the study or those who have not recovered from adverse events due to agents or therapies administered for treatment of prostate cancer more than 4 weeks earlier (except urinary, rectal, and sexual side effects related to prostatectomy or radiotherapy are permitted)
  5. Subjects who have had any surgical procedure (i.e. TURP, etc.) within 4 weeks prior to entering the study.
  6. Subjects who are receiving any other investigational agents.
  7. Significant cardiovascular disease, including:

    • Symptomatic left ventricular dysfunction or known baseline left ventricular ejection fraction (LVEF) by multigated acquisition scan (MUGA) or echocardiogram (ECHO) of < lower limit of institutional normal (LLN). "Symptomatic" is defined as New York Heart Association (NYHA) Class II or greater. Note: MUGA and ECHCO do NOT need to be measured to establish eligibility for this study.
    • Uncontrolled hypertension (in the opinion of the treating provider).
    • Myocardial infarction, severe angina, or unstable angina within 6 months prior to administration of first dose of study drug.
    • History of serious ventricular arrhythmia (i.e., ventricular tachycardia or ventricular fibrillation) within 12 months of first dose of study drug.
    • Uncontrolled cardiac arrhythmias.
    • Coronary or peripheral artery bypass graft within 6 months of first dose of study drug.
    • History of CVA, TIA, or rest claudication within 6 months of first dose of study drug.
  8. Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements (in the opinion of the treating provider).
  9. Subjects with any condition (e.g., gastrointestinal tract disease resulting in an inability to take oral medication or a requirement for IV alimentation, prior surgical procedures affecting absorption, or active peptic ulcer disease) that impairs the ability to swallow and retain enzalutamide are excluded.
  10. History of another invasive cancer within 5 years of randomization with the exceptions of (a) non-melanoma skin cancers and (b) American Joint Committee on Cancer (AJCC) Stage 0 or 1 cancers that have a remote probability of recurrence, in the opinion of the treating physician, in consultation with the principal investigator.
  11. Known or suspected brain metastasis or leptomeningeal disease.
  12. History of seizure or any condition that may predispose to seizure (e.g., prior cortical stroke, significant brain trauma) at any time in the past. Also, history of loss of consciousness or transient ischemic attack within 12 months of the Day 1 visit.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02256111


Locations
Layout table for location information
United States, New York
Memorial Sloan Kettering Cancer Center
New York, New York, United States, 10017
United States, North Carolina
Duke University Medical Center
Durham, North Carolina, United States, 27710
Sponsors and Collaborators
Duke University
Investigators
Layout table for investigator information
Principal Investigator: Michael Harrison, MD Duke University
  Study Documents (Full-Text)

Documents provided by Duke University:

Layout table for additonal information
Responsible Party: Duke University
ClinicalTrials.gov Identifier: NCT02256111     History of Changes
Other Study ID Numbers: Pro00053924
First Posted: October 3, 2014    Key Record Dates
Results First Posted: April 18, 2019
Last Update Posted: April 18, 2019
Last Verified: March 2019
Additional relevant MeSH terms:
Layout table for MeSH terms
Androgens
Prostatic Neoplasms
Genital Neoplasms, Male
Urogenital Neoplasms
Neoplasms by Site
Neoplasms
Genital Diseases, Male
Prostatic Diseases
Hormones
Hormones, Hormone Substitutes, and Hormone Antagonists
Physiological Effects of Drugs